Clinical Trial

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-11; most recent amendment 2024-04-29.
Status change: Not Yet Recruiting → Recruiting 2023-05-22
Trial Details
NCT Number NCT05868174
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma
Enrollment 36 participants
Start Date 2023-05-23
Primary Completion 2024-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-01